Sonoma Pharmaceuticals
SNOA
13 hedge funds and large institutions have $1.01M invested in Sonoma Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
60% more capital invested
Capital invested by funds: $628K → $1.01M (+$379K)
0.04% more ownership
Funds ownership: 0.36% → 0.4% (+0.04%)
7% less funds holding
Funds holding: 14 → 13 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$75.6K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$42K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$841 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$120 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
Bard Associates
Chicago,
Illinois
|
-$32.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $586K | +$75.6K | +629 | +18% |
|
|
BA
2
Bard Associates
Chicago,
Illinois
| $332K | -$32.6K | -271 | -10% |
|
|
3
Acadian Asset Management
Boston,
Massachusetts
| $61K | +$42K | +350 | +449% |
|
4
BlackRock
New York
| $24K | – | – | – |
|
5
Morgan Stanley
New York
| $2K | – | – | – |
|
6
Osaic Holdings
Scottsdale,
Arizona
| $1K | – | – | – |
|
|
PAG
7
Private Advisor Group
Morristown,
New Jersey
| $1K | +$841 | +7 | New |
|
|
RE
8
RBC Europe
London,
United Kingdom
| $14 | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$3K | -30 | Closed |
|
|
10
Victory Capital Management
San Antonio,
Texas
| – | -$2K | -29 | Closed |
|
|
11
Bank of America
Charlotte,
North Carolina
| – | +$120 | +1 | +50% |
|
SNOA Hedge Fund Activity: Q2 2020 in Review
13 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2020, worth a combined $1.01M — up 60% from $628K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SNOA and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $75.6K. The largest seller was Bard Associates, cutting an estimated $32.6K.
- 13 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2020, down from 14 in Q1 2020.
- Funds reported $1.01M of Sonoma Pharmaceuticals stock for Q2 2020, up 60% quarter-over-quarter.
- 1 fund opened new Sonoma Pharmaceuticals positions in Q2 2020 and 2 closed out, a net change of -1 holder.
- The largest Sonoma Pharmaceuticals buyer in Q2 2020 was Renaissance Technologies, an estimated $75.6K added.
- The largest Sonoma Pharmaceuticals seller in Q2 2020 was Bard Associates, an estimated $32.6K sold.
Based on aggregated 13F filings for Q2 2020.